History A 30+ year journey with a relentless focus on science

Our commitment to patients extends well beyond our labs. We are proud to support the communities we serve, to embrace a culture and business model of patients over profits and to hold the highest ethical standards when it comes to patient well-being.

Leonard S. Schleifer, MD, PhD: Founder of Regeneron

Regeneron is founded by Leonard S. Schleifer, MD, PhD, a young neurologist and assistant professor at Cornell University Medical College

George D. Yancopoulos, MD, PhD a molecular immunologist launched Regeneron in 1989.

George D. Yancopoulos, MD, PhD, a highly regarded young molecular immunologist at Columbia University, joins Regeneron

Science publishes our first paper, which becomes the most highly cited neurobiology paper of the year

We announce a collaboration to develop neurotrophic factors

REGN stock begins trading publicly on the NASDAQ; the initial public offering (IPO) raises $91.6 million

Clinical development of our first investigational drug, a neurotrophic factor, begins

Regeneron acquired space for a drug manufacturing facility in 1993.

We acquire space for a drug manufacturing facility in Rensselaer, NY, years before having an FDA-approved medicine

P. Roy Vagelos, MD becomes Chairman of the Board in 1995.

Industry legend P. Roy Vagelos, MD, becomes Chairman of the Board, a position he still holds today

Dr. Vagelos, another businessman-scientist who had previously led Merck's R&D division, encourages us to focus our research on disease settings where the biological profile can be fully characterized and the clinical benefit evaluated more quickly

The Phase 3 trial of our first neurotrophic factor does not achieve its primary endpoint, and though the team is disappointed, we regroup to focus on new therapeutic solutions

George Yancopoulos, MD, PhD becomes 11th most highly cited scientists in 1999.

George Yancopoulos, MD, PhD, becomes the decade's 11th most highly cited scientist in the world

Our investigational medicine rilonacept begins clinical exploration

Our investigational medicine rilonacept begins clinical exploration
First paper on VelociGene® is published in 2003.

Our first paper on VelociGene® is published, introducing the world to our proprietary Veloci technologies

We become one of the original sponsors of the Westchester Science & Engineering Fair (WESEF) to support and reward scientific excellence in promising high school students

Our investigational medicine aflibercept begins clinical development

Sarilumab, our first fully human antibody, enters clinical development

A collaboration with Bayer HealthCare focuses on developing aflibercept outside the U.S.

Collaboration with Sanofi using VelocImmune® technology platform in 2007

A collaboration with Sanofi focuses on developing fully human antibodies using our VelocImmune® technology platform

FDA approval of ARCALYST injection in 2008

The FDA approves our first medicine, ARCALYST® (rilonacept) Injection

*In 2021, Kiniksa assumed U.S. commercial rights to ARCALYST for all approved indications

We expand and extend our antibody collaboration with Sanofi

Our investigational medicine alirocumab begins clinical development

We hire our 1,000th employee and move into new buildings on our Tarrytown campus

Regeneron hires its 1000th employee in 2009.
Regeneron begins to sponsor BioBus in 2010.

We begin sponsorship of the BioBus, a mobile laboratory, to drive hands-on science education in underserved school districts

EYLEA Injection is FDA approved in 2011.

The FDA approves EYLEA® (aflibercept) Injection for its first indication

Our President and CEO, Leonard S. Schleifer, is named Ernst & Young's 2011 New York Entrepreneur Of The Year®

Named biotech company of the year in 2012

The Science Top Employer survey names us the #1 employer in the global biopharmaceutical industry

Scrip Intelligence names us Biotech Company of the Year

We announce the first recipients of our annual Regeneron Prize for Creative Innovation

Our European business office opens in Dublin, Ireland

Regeneron office opens in Dublin, Ireland in 2013.

Scrip Intelligence names Len and George as the "Management Team of the Year"

Regeneron Genetics Center launches in 2014.

The Regeneron Genetics Center®, a new human genetics initiative, officially launches

We initiate the STEM Teaching Fellowship, a joint effort with the STEM Leadership Center, to develop a highly trained science teacher community, and Sci2Med Academy in collaboration with Yonkers Partners in Education to broaden career horizons for students who are underrepresented in the science fields. Learn more about our initiatives

We begin building our first ex-U.S. IOPS site in Limerick, Ireland

PRALUENT Injection received FDA approval in 2015.

The FDA approves PRALUENT® (alirocumab) Injection our fourth FDA-approved medicine and first FDA-approved fully human monoclonal antibody

We launch a major new immuno-oncology collaboration with Sanofi

Regeneron becomes new title sponsor for the Science Talent Search in 2016.

We are named as the new title sponsor for the Science Talent Search (just the third in the prestigious competition's 75-year history)

DUPIXENT Injection is FDA approved in 2017.

The FDA approves DUPIXENT® (dupilumab) Injection, our fifth FDA-approved medicine

KEVZARA Injection is FDA approved in 2017.

The FDA approves KEVZARA® (sarilumab) Injection, our sixth FDA-approved medicine and second fully human monoclonal antibody

Recognized on the Civic 50 list of most community-minded companies in the United States

DUPIXENT Injection is FDA approved for a new indication in 2018.

The FDA approves a new indication for DUPIXENT® (dupilumab) Injection

Libtayo Injection receives FDA approval in 2018.

The FDA approves Libtayo® (cemiplimab-rwlc) Injection, our seventh FDA-approved medicine

Regeneron DNA Learning Center dedicated to student science education.
Regeneron became a new sponsor of the International Science and Engineering Fair in 2019.

Regeneron and Cold Spring Harbor Laboratory unveil new dedicated laboratories for student science education. Society for Science announces Regeneron as new sponsor of the International Science and Engineering Fair

The FDA and European Commission approves new indications for EYLEA® (aflibercept) injection, DUPIXENT® (dupilumab) injection, Libtayo® (cemiplimab) injection and PRALUENT® (alirocumab) injection.

Regeneron debuts on the prestigious Dow Jones Sustainability World Index of Most Sustainable Companies.

The FDA approves an expanded indication for DUPIXENT® (dupilumab) injection in 2020

The FDA approves an expanded indication for DUPIXENT® (dupilumab) injection

The FDA approves Inmazeb (atoltivimab, maftivimab, and odesivimab-ebgn).

The FDA approves InmazebTM (atoltivimab, maftivimab, and odesivimab-ebgn)

Regeneron discovers and develops a novel COVID-19 antibody cocktail in record time; the FDA authorizes it for emergency use later the same year

Regeneron named Science magazine’s #1 biopharma company for the seventh time

George D. Yancopoulos, MD, PhD: Co-Founder, President and Chief Scientific Officer

There may be no other thing you can do that is more rewarding than to really move the human condition forward

George D. Yancopoulos, MD, PhD

President and Chief Scientific Officer

to top